Bromley, RebeccaAdab, NaghmeBluett-Duncan, MattClayton-Smith, JillChristensen, JakobEdwards, KatherineGreenhalgh, JanetteHill, Ruaraidh AJackson, Cerian FKhanom, SoniaMcGinty, Ronan NTudur Smith, CatrinPulman, JenniferMarson, Anthony G2023-09-062023-09-062023-08-29Cochrane Database Syst Rev . 2023 Aug 29;8(8):CD0102241469-493X10.1002/14651858.CD010224.pub337647086http://hdl.handle.net/20.500.14200/2116Background: Prenatal exposure to certain anti-seizure medications (ASMs) is associated with an increased risk of major congenital malformations (MCM). The majority of women with epilepsy continue taking ASMs throughout pregnancy and, therefore, information on the potential risks associated with ASM treatment is required. Objectives: To assess the effects of prenatal exposure to ASMs on the prevalence of MCM in the child.enCopyright © 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.NeurologyPaediatricsObstetrics. MidwiferyEvidence Summary